CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-06-14): Treating HCV improves insulin resistance in HIV coinfection

Clinical

Treating HCV improves insulin resistance in HIV coinfection

Last Updated: 2012-06-14 17:40:30 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients with hepatitis C virus (HCV) and the human immunodeficiency virus (HIV), pegylated interferon and ribavirin therapy for the hepatitis produce significant metabolic improvements as well.

The effect lasts only while treatment continues, however, leaving just a modest persistent improvement in insulin resistance, researchers reported online May 4th in Clinical Infectious Diseases.

Dr. Adeel A. Butt of the University of Pittsburgh School of Medicine and colleagues studied 98 HIV/HCV patients who were participating in a study of the effect of peginterferon and ribavirin maintenance therapy on fibrosis progression. Evaluation of metabolic parameters was a pre-specified secondary aim.

Fasting levels of low-density lipoprotein, high-density lipoprotein, and total cholesterol all fell significantly while on treatment, by a median of 13, 15 and 6 mg/dL, respectively, after 16 weeks of treatment and 20, 16 and 5 mg/dL at treatment week 64.

Values were almost back to baseline at 24 weeks after treatment ended.

Triglycerides increased significantly during the first 16 weeks of treatment, by 30 mg/dL, but by week 64 the increase was no longer significant and by 24 weeks after treatment ended those levels too had return nearly to baseline.

As for insulin resistance, values of the homeostasis model assessment showed a gradual modest decline during treatment that did still persist at 24 weeks after completion.

"Whether this improvement eventually translates into a decrease in incidence of overt diabetes mellitus, or improvement of glycemic controls in those who are already diabetic, requires further investigation," the authors say.

In email to Reuters Health, Dr. Butt noted, "The effect of HCV treatment upon metabolic parameters is not well understood. Our study demonstrated a modest improvement in insulin resistance with anti-HCV treatment. This suggests an added benefit of treatment, and further justifies the need to identify and treat HCV infected patients."

He concluded, "Larger studies are needed to confirm whether treatment decreases the rate of incident diabetes in HCV infected persons."

SOURCE: http://bit.ly/M8Rzdi

Clin Infect Dis 2012.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.